NCT03337477 - A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 13, 2018

Primary Completion Date

December 21, 2018

Study Completion Date

December 21, 2018

Conditions

Hyperkalemia

Interventions

DRUG

Placebo

Suspension administered orally for a treatment period of 24h. 2 sachets administered up to three times over 10h (at 0, 4 and 10h).

DRUG

Sodium Zirconium Cyclosilicate(ZS)

Suspension administered orally for a treatment period of 24h. Single dose contains 2 sachets of ZS 5g. 10g administered up to three times over 10h (at 0, 4 and 10h).

DRUG

Insulin

Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.

DRUG

Glucose

Glucose 25g administered IV \<15 minutes before the insulin.

DRUG

Insulin

Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.

DRUG

Glucose

Glucose 25g administered IV \<15 minutes before the insulin.

Trial Locations (25)

6700

Research Site, Esbjerg

7400

Research Site, Herning

11794

Research Site, Stony Brook

27157

Research Site, Winston-Salem

27710

Research Site, Durham

28100

Research Site, Novara

36106

Research Site, Montgomery

48073

Research Site, Royal Oak

48201

Research Site, Detroit

48202

Research Site, Detroit

48235

Research Site, Detroit

57025

Research Site, Piombino

63110

Research Site, St Louis

77030

Research Site, Houston

79905

Research Site, El Paso

85008

Research Site, Phoenix

115516

Research Site, Moscow

121374

Research Site, Moscow

150062

Research Site, Yaroslavl

198205

Research Site, Saint Petersburg

390039

Research Site, Ryazan

614990

Research Site, Perm

620039

Research Site, Yekaterinburg

650002

Research Site, Kemerovo

650066

Research Site, Kemerovo